Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura - Scorecard - MDSpire

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.

  • By

  • Taylor P. Robichaux

  • Kathryn E. Dane

  • P. Christopher Parish

  • Justin R. Arnall

  • Donald C. Moore

  • January 9, 2026

  • 15 min

Share

Clinical Scorecard: Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

At a Glance

CategoryDetail
ConditionCongenital Thrombotic Thrombocytopenic Purpura (cTTP)
Key MechanismsDeficiency of ADAMTS13 leads to unregulated circulation of ultra-large vWF multimers, causing increased platelet adhesion and aggregation.
Target PopulationPediatric and adult patients with congenital TTP.
Care SettingHospital and outpatient settings for management and prophylaxis.

Key Highlights

  • cTTP is an autosomal recessive disorder caused by mutations in the ADAMTS13 gene.
  • Characterized by microvascular thrombosis, consumptive thrombocytopenia, and microangiopathic hemolytic anemia.
  • Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved treatment for cTTP.
  • rADAMTS13 allows for restoration of ADAMTS13 activity, reducing thrombotic complications.
  • Traditional treatment involves plasma infusions, which carry risks of transfusion reactions.

Guideline-Based Recommendations

Diagnosis

  • ADAMTS13 activity level < 10% confirms cTTP diagnosis.
  • Genetic sequencing should be performed if anti-ADAMTS13 IgG autoantibodies are negative.

Management

  • Prophylactic or on-demand administration of rADAMTS13 is recommended.
  • Plasma infusions may be used for acute episodes but are burdensome.

Monitoring & Follow-up

  • Monitor ADAMTS13 activity levels and clinical symptoms post-treatment.

Risks

  • Risks associated with plasma transfusions include transfusion reactions and thrombotic events.

Patient & Prescribing Data

Patients with diagnosed congenital TTP, including pediatric and adult populations.

rADAMTS13 provides a safer alternative to plasma infusions, especially for patients unable to receive blood products.

Clinical Best Practices

  • Consider genetic testing for patients with suspected cTTP.
  • Utilize rADAMTS13 for both prophylactic and on-demand treatment strategies.
  • Regularly assess for signs of thrombotic microangiopathy and adjust treatment accordingly.

References

Original Source(s)

Recombinant ADAMTS13: An Enzyme Replacement Therapy for the Management of Congenital Thrombotic Thrombocytopenic Purpura

  • by Taylor P. Robichaux, Kathryn E. Dane, P. Christopher Parish, Justin R. Arnall, Donald C. Moore

  • January 9, 2026

Related Content

Obstacles to Accessing Health Care and Cancer Screening Services

Extended-course transcutaneous tibial nerve stimulation for pediatric overactive bladder: a 6-Month prospective single-arm study

Children’s Health-Related Quality of Life After Brachial Plexus Birth Injury